Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics
J. Clin. Invest. Patrick Flood-Page, et al. 112:1029 doi:10.1172/JCI17974 [Go to this article.]

Figure 3
Representative photomicrographs of tenascin immunoreactivity in the reticular basement membrane from a normal subject (a) and from an asthmatic subject pretreatment (b) and posttreatment (c) with anti–IL-5. Lumican immunoreactivity from a normal subject (d) and from pretreatment (e) and posttreatment (f) with anti–IL-5 is also shown. Examples of procollagen III immunoreactivity pretreatment (g) and posttreatment (h) with anti–IL-5 are presented, although the decrease shown was not typical of all subjects. i shows an example of isotype control immunoreactivity. Immunoreactivity of ECM proteins is shown in green. Sections were counterstained with DAPI (blue).